Multi-specific antibodies and cell therapies enter phase 1
Assets targeting PSMA and KRAS G12V, plus another gamma-delta Car-T therapy, feature among recently disclosed first-time clinical trial entrants.
First phase 1 starters challenge Pluvicto and Revolution
The latest first-in-human trial entrants include several novel mechanisms, a PSMA radioconjugate and a new pan-KRAS challenger.
Triple meeting 2023 – Revolution’s KRAS revolution promise draws fans
Phase 1 data suggest the group’s KRAS G12C inhibitor has activity, crucially in KRAS-experienced patients.
Three mystery phase 1 entrants
Bristol, AbbVie and Jiangsu HengRui move to enter clinical trials with undisclosed mechanisms of action.
A flurry of first-in-human trial initiations
Projects from Affini-T, Bolt, Chimeric and Alentis, all hitting novel targets, as well as one from A2 using an old one, are set for first clinical trial entry.
Bridge mirrors Black Diamond and Blueprint’s search for something better
The companies have all switched to improved fourth-generation EGFR projects in lung cancer, a fact that likely shows how competitive this field has become.
Approval milestones – Hutchmed, SpringWorks, Crispr and Ionis eye firsts
A work-stretched US FDA has several key approval application still to review by the end of 2023.
Point looks to make a year-end Splash
The company’s radiopharmaceutical PNT2002 faces a major fourth-quarter catalyst, and US filing could follow.
A subcutaneous answer to PD-1’s patent problem
PD-(L)1 players are increasingly looking to subcutaneous delivery to maintain market share, and next month brings a major catalyst.
